Pfizer's positive antiviral news raises hopes for a new easy-to-take treatment for COVID-19, and cases start to rise again in California

Pfizer shares soared Friday after the company released interim data from a late-stage trial of its COVID-19 antiviral that showed it to be highly effective, raising hopes that a new treatment for the novel coronavirus that is easy to administer may soon be allowed.

iframe.twitter-tweet { width: 100% !important; } Experts have said oral treatments for COVID-19 would be a game changer as they would allow patients to be treated at home, while current treatments need to be conducted in a clinical setting using intravenous or subcutaneous infusion. The U.S. is still averaging more than 1,100 COVID deaths a day, according to a New York Times tracker, although cases and hospitalizations are declining. However, hot spots like Colorado remain, and hospitals there are struggling. And cases are starting to climb again in California and New Mexico, the tracker shows.The Centers for Disease Control and Prevention’s vaccine tracker is showing that 193 million people living in the U.S.

See: WHO warns Europe could see 500,000 more COVID-19 deaths by February amid uneven vaccine take-up, and U.S. starts to give kids as young as 5 their shots Japan will reopen its borders for businesspeople and students starting Monday, the Nikkei reported. But restrictions on overseas tourist arrivals will remain in place for now.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Pfizer says its antiviral pill slashes risk of severe COVID-19 by 89%(Reuters) -Pfizer Inc's experimental antiviral pill to treat COVID-19 was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday, offering what could be a promising new weapon in the fight against the pandemic. The trial's results suggest that the oral drug surpasses Merck & Co Inc's pill, molnupiravir, which was shown last month to halve the risk of dying or being hospitalized for COVID-19 patients at high risk of serious illness. Pfizer's pill, with the brand name Paxlovid, could secure U.S. regulatory approval by the end of the year.
Source: YahooNews - 🏆 380. / 59 Read more »

Pfizer says its antiviral pill slashes risk of severe COVID-19 by 89%Pfizer Inc's experimental antiviral pill to treat COVID-19 was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday, offering what could be a promising new weapon in the fight against the pandemic.
Source: Reuters - 🏆 2. / 97 Read more »